Cue Biopharma, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: CUE · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1645460
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Virtual Meeting, Shareholder Voting, Cue Biopharma
TL;DR
<b>Cue Biopharma, Inc. is holding its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, requiring advance registration for online attendance and voting.</b>
AI Summary
Cue Biopharma, Inc. (CUE) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Cue Biopharma, Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 9:00 a.m. Eastern Time. The meeting will be conducted exclusively online via the Internet at www.proxydocs.com/CUE. Stockholders must register in advance by June 4, 2024, at 5:00 p.m. Eastern Time to attend and vote. Stockholders of record as of April 12, 2024, are entitled to vote at the meeting. Voting can be done by proxy over the Internet, by telephone, or by mail.
Why It Matters
For investors and stakeholders tracking Cue Biopharma, Inc., this filing contains several important signals. The virtual format allows for broader participation and electronic voting, potentially increasing shareholder engagement. The deadline for advance registration (June 4, 2024) is critical for shareholders to receive access links and participate in the meeting.
Risk Assessment
Risk Level: low — Cue Biopharma, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Stockholders should review the proxy materials and vote their shares by the specified deadlines to ensure their participation in corporate governance decisions.
Key Numbers
- June 5, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 9:00 a.m. Eastern Time — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)
- April 12, 2024 — Record Date (Stockholders of record on this date are entitled to vote.)
- June 4, 2024 — Registration Deadline (Deadline to register in advance for the virtual meeting.)
- 5:00 p.m. Eastern Time — Registration Deadline Time (Time of the advance registration deadline.)
Key Players & Entities
- Cue Biopharma, Inc. (company) — Filer and Registrant
- June 5, 2024 (date) — Date of Annual Meeting
- www.proxydocs.com/CUE (url) — Link to attend and vote at the virtual meeting
- June 4, 2024 (date) — Advance registration deadline
- April 12, 2024 (date) — Record date for voting eligibility
- 40 Guest Street Boston, Massachusetts 02135 (address) — Company's business and mailing address
- 617-949-2680 (phone) — Company's business phone number
- Imagen Biopharma, Inc. (company) — Former company name
FAQ
When did Cue Biopharma, Inc. file this DEF 14A?
Cue Biopharma, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Cue Biopharma, Inc. (CUE).
Where can I read the original DEF 14A filing from Cue Biopharma, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cue Biopharma, Inc..
What are the key takeaways from Cue Biopharma, Inc.'s DEF 14A?
Cue Biopharma, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: Cue Biopharma, Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 9:00 a.m. Eastern Time.. The meeting will be conducted exclusively online via the Internet at www.proxydocs.com/CUE.. Stockholders must register in advance by June 4, 2024, at 5:00 p.m. Eastern Time to attend and vote..
Is Cue Biopharma, Inc. a risky investment based on this filing?
Based on this DEF 14A, Cue Biopharma, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading Cue Biopharma, Inc.'s DEF 14A?
Stockholders should review the proxy materials and vote their shares by the specified deadlines to ensure their participation in corporate governance decisions. The overall sentiment from this filing is neutral.
How does Cue Biopharma, Inc. compare to its industry peers?
Cue Biopharma operates in the pharmaceutical preparations industry, focusing on developing novel immunotherapies.
Are there regulatory concerns for Cue Biopharma, Inc.?
The filing is a routine DEF 14A, subject to SEC regulations governing proxy solicitations and annual shareholder meetings.
Industry Context
Cue Biopharma operates in the pharmaceutical preparations industry, focusing on developing novel immunotherapies.
Regulatory Implications
The filing is a routine DEF 14A, subject to SEC regulations governing proxy solicitations and annual shareholder meetings.
What Investors Should Do
- Review the proxy statement for details on director nominees and any proposals to be voted on.
- Register in advance by June 4, 2024, to receive access to the virtual annual meeting.
- Vote your shares by proxy (Internet, phone, or mail) to ensure your vote is counted.
Key Dates
- 2024-06-05: Annual Meeting of Stockholders — Key date for shareholder voting and participation in corporate decisions.
- 2024-04-12: Record Date — Determines which shareholders are eligible to vote at the annual meeting.
- 2024-06-04: Advance Registration Deadline — Crucial deadline for shareholders to register for the virtual meeting.
Year-Over-Year Comparison
This filing is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, indicating a routine procedural update from the previous year's filings.
Filing Stats: 4,871 words · 19 min read · ~16 pages · Grade level 9.9 · Accepted 2024-04-26 16:02:26
Filing Documents
- cue-def14a-2024_proxy.htm (DEF 14A) — 937KB
- img88781609_0.jpg (GRAPHIC) — 31KB
- img88781609_1.jpg (GRAPHIC) — 31KB
- img88781609_2.jpg (GRAPHIC) — 31KB
- img88781609_3.jpg (GRAPHIC) — 34KB
- img88781609_4.jpg (GRAPHIC) — 37KB
- img88781609_5.jpg (GRAPHIC) — 104KB
- img88781609_6.jpg (GRAPHIC) — 71KB
- 0000950170-24-049072.txt ( ) — 1404KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 22 EQUITY COMPENSATION PLAN INFORMATION 30 TRANSACTIONS WITH RELATED PERSONS 31
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 32 PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 34 PROPOSAL 3: ADVISORY VOTE ON EXECUTIVE COMPENSATION 35 STOCKHOLDER PROPOSALS FOR OUR 2025 ANNUAL MEETING 36 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 36 OTHER MATTERS 36 Table of Contents CUE BIOPHARMA, INC. 40 Guest Street Boston, Massachusetts 02135 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on Wednesday, June 5, 2024 INFORMATION CONCER NING SOLICITATION AND VOTING This Proxy Statement contains information about our 2024 annual meeting of stockholders, or the Annual Meeting. The meeting will be held on Wednesday, June 5, 2024 at 9:00 a.m. Eastern Time. The Annual Meeting will be held exclusively via the Internet in a virtual meeting format at www.proxydocs.com/CUE . There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. Except where the context otherwise requires, references to “Cue Biopharma,” “the Company,” “we,” “us,” “our” and similar terms refer to Cue Biopharma, Inc. and its consolidated subsidiary. References to our website are inactive textual references only and the contents of our website are not incorporated by reference into this Proxy Statement. This Proxy Statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by our board of directors for use at the Annual Meeting and at any adjournment or postponement of that meeting. All proxies will be voted in accordance with the instructions they contain. If you do not specify your voting instructions on your proxy, it will be voted in accordance with the recommendations of our board of directors. We are making this Proxy Statement, the related proxy card and our annual report to stockholders for the fiscal y